Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025)

Amylyx Pharmaceuticals has reported Change in Interest Receivables over the past 5 years, most recently at -$6000.0 for Q4 2025.

  • Quarterly results put Change in Interest Receivables at -$6000.0 for Q4 2025, up 89.29% from a year ago — trailing twelve months through Dec 2025 was -$24000.0 (up 93.31% YoY), and the annual figure for FY2025 was -$24000.0, up 93.31%.
  • Change in Interest Receivables for Q4 2025 was -$6000.0 at Amylyx Pharmaceuticals, down from $55000.0 in the prior quarter.
  • Over the last five years, Change in Interest Receivables for AMLX hit a ceiling of $609000.0 in Q2 2023 and a floor of -$726000.0 in Q3 2023.
  • Median Change in Interest Receivables over the past 5 years was -$6000.0 (2025), compared with a mean of -$52411.8.
  • Peak annual rise in Change in Interest Receivables hit 4975.0% in 2023, while the deepest fall reached 25400.0% in 2023.
  • Amylyx Pharmaceuticals' Change in Interest Receivables stood at $2000.0 in 2021, then crashed by 27500.0% to -$548000.0 in 2022, then skyrocketed by 163.32% to $347000.0 in 2023, then tumbled by 116.14% to -$56000.0 in 2024, then skyrocketed by 89.29% to -$6000.0 in 2025.
  • The last three reported values for Change in Interest Receivables were -$6000.0 (Q4 2025), $55000.0 (Q3 2025), and -$7000.0 (Q2 2025) per Business Quant data.